Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
收藏数据链接：
官方服务：
资源简介：
Cell lines with their demographics and characteristics for primary endometrioid cancers
创建时间：
2025-09-11
